Sue primarily covers US drug, biologic, vaccine and biosimilar regulation and policy across therapeutic areas, with an emphasis on advisory committee reviews, FDA approvals and use of expedited review pathways. Sue has reported on the prescription and over-the-counter drug industries since 1999 for various publications now under the Citeline umbrella, including Pink Sheet and Scrip. Previously she worked as an editor for Mealey's Litigation Reports (now part of Lexis-Nexis), writing about asbestos, toxic tort and fen-phen litigation. She grew up in South Jersey and spends her free time watching youth sports, gardening, walking and hiking, although she'd rather be at the beach.

Latest from Sue Sutter

Hims & Hers’ Compounded Semaglutide Pill Triggers US FDA Enforcement

The Health and Human Services general counsel referred the online health platform to the Justice Department to investigate potential violations of the Food, Drug and Cosmetic Act after the firm announced it would offer a compounded version of Novo Nordisk’s oral Wegovy.

Pink Sheet Podcast: US FDA Hiring Improves, But Can The Agency Avoid Oversight Erosion?

As the FDA sees another quarter with a net loss of employees in CDER and CBER, Pink Sheet editors discuss the potential impact and where it could manifest.

US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says

Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.

US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request

The clinical and statistical review teams favored a complete response letter for the vasculitis treatment, while the review division and office directors supported approval.

US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says

Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.

US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says

Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.